Cardiac AI ROI: Proving Value Beyond the Hype

Everyone sees the hockey-stick growth projections for healthcare AI, $2.2 billion in 2026 to $14.8 billion by 2033, and the money follows. But for cardiovascular platforms, investors get blinded by the promise of cool algorithms and big valuations, forgetting the granular reality of how value is actually created in a hospital. For these platforms, a real return on investment (ROI) doesn’t come from a clever algorithm. It comes from hard clinical validation and being able to integrate into the messy, complex workflows doctors and nurses already use. You have to shift your thinking away from the AI hype and ask a simple, objective question: does this thing actually work better than the current standard of care?

Beyond the Hype: Does the AI Beat What Doctors Do Now?

To figure out if a healthcare AI tool is actually worth anything, especially in a high-stakes field like cardiology, you have to benchmark it against what doctors are already doing. We used a scoring rubric that zeroes in on two things: clinical validation and capital efficiency. It’s about looking at these cardiovascular AI platforms for their real-world ability to improve patient outcomes and save hospitals money, not just their tech specs. This is what investors and VCs need to do to tell the difference between a good story and a company that can produce verifiable financial results. ROI isn’t one number. It’s a range of outcomes that depends entirely on the clinical context. The standard of care in cardiology is already well-defined with established protocols and treatment guidelines. For an AI solution to justify its cost, it must make those workflows substantially better or offer a completely new approach that’s more effective and economically sound. That means you need to find platforms that can show you improved clinical endpoints, not just fuzzy administrative efficiencies or theoretical savings.

Viz.ai: Concrete Triage Speedups and Clinical Endpoints

Viz.ai is a perfect example of an AI platform that delivers a clear ROI by fixing a real problem in acute stroke and cardiovascular triage. Their AI platform analyzes medical images and pings specialists about time-sensitive cases like stroke, directly attacking the biggest bottleneck in stroke care: the time from symptom onset to treatment. Every single minute you save in treating a stroke can preserve millions of neurons, which has a direct line to better patient outcomes and slashing long-term care costs. And they have the data to prove it. Clinical trials for Viz.ai consistently show major drops in treatment time. For example, studies have shown they can cut the median time to notify a stroke specialist by over 30 minutes and reduce the median time to treatment by about 20 minutes Viz.ai clinical trial data on time to treatment reduction. These aren’t just operational tweaks. This translates directly to better Modified Rankin Scale (mRS) scores for patients, which means lower bills for rehab and long-term care for the health system. It’s the definition of value-based care: better outcomes for patients, potentially at a lower total cost. Viz.ai’s success comes from its design as a SaMD (Software as a Medical Device) that slots right into a hospital’s existing imaging infrastructure and gives doctors actionable information that makes them faster. The fact that they pulled in a $100 million Series D round, pushing them to a $1.2 billion valuation with backing from Tiger Global, shows that investors see the value in their clinically proven impact and clear path to getting paid, including potential NTAP eligibility. This is a company that figured out the 510(k) clearance process and built a strong data moat with its algorithms and real-world evidence.

Tempus AI: Precision Medicine and the Long Game of Genomic Data

Tempus AI is a different kind of bet, but it shows the potential ROI in precision medicine and genomic profiling. With funding from GV and a massive $12.8 billion valuation, Tempus gives physicians data to personalize cancer treatment, and they’re expanding that model into cardiovascular risk and treatment. Their whole strategy is built on creating a gigantic private library of clinical and molecular data, then using AI to find patterns that predict how a patient will respond to a certain treatment. The ROI is a longer-term proposition based on the power of precision medicine. By figuring out the right drug for the right patient upfront using their genomic profile, Tempus helps doctors avoid prescribing ineffective therapies, reduce side effects, and in the end improve survival. What does this mean for heart disease? It could mean identifying patients with a high genetic risk for a heart attack, optimizing their meds to prevent problems, or guiding doctors in choosing advanced therapies. While we’re still waiting on peer-reviewed studies showing direct cost savings for Tempus in cardiology, the logic is solid: making better-informed decisions prevents wasted spending and leads to better outcomes. Their ability to hoard huge, proprietary datasets gives them a significant competitive advantage (their data moat). Investors in Tempus are betting that AI-driven genomic analysis will become the standard of care, changing how value is delivered across dozens of diseases, including cardiology.

Olive AI: A Cautionary Tale of Operational Over-Promise

The story of Olive AI is the poster child for what happens when you over-promise on AI and should serve as a cautionary tale for investors. In sharp contrast to Viz.ai’s clinical focus and Tempus AI’s long-term data play, Olive AI’s flameout is a lesson in what not to do. After raising an incredible $902 million from investors including Tiger Global, they promised to fix healthcare’s back-office mess through automation. The initial valuation was huge because everyone loved the idea of using AI to get rid of mind-numbing administrative work and save a ton of money. But the post-mortem on Olive AI’s collapse shows where they went wrong: they focused entirely on automating administrative tasks without tying it back to clinical workflows or proving a sustained ROI. The idea of automating repetitive tasks is great on a PowerPoint slide, but the reality of getting it to work across a hospital’s diverse and often ancient IT systems was far harder and less impactful than they sold. The promised cost savings never showed up at the enterprise level, or the implementation was so expensive and complex it wiped out any potential benefits. The lesson from Olive’s failure is that real ROI in a value-based care world has to be tied to hard clinical endpoints, not just automating paperwork. Operational efficiency is nice, but it doesn’t create the kind of deep, patient-focused value needed to survive. This is why you have to grill companies during due diligence on their GMLP compliance, QMS/ISO 13485 certification, and whether their implementation timelines are even remotely realistic.

The Methodology: A Scoring Rubric for Clinical Validation and Capital Efficiency

So how do you actually score these companies? Our evaluation uses a comparative rubric that prioritizes the two things that matter for ROI in cardiovascular AI under a value-based care model: clinical validation and capital efficiency. Clinical Validation: This looks at how strong the evidence is that the platform actually works. Key questions include:

• Peer-Reviewed Clinical Trials: Do they have real clinical trial data, randomized controlled trials (RCTs) or solid real-world evidence (RWE), showing they improve patient outcomes, like lowering mortality or readmission rates?
• Regulatory Clearances: Did they get through the FDA? A 510(k) clearance or De Novo classification, especially if they got a Breakthrough Device Designation, is a strong signal of legitimacy and market readiness.
• Integration with Standard of Care: How well does the AI tool actually fit into a doctor’s day? Does it make an existing workflow better or replace it with something demonstrably superior?
• Data Moat and Algorithmic Robustness: How good is their data? Is it proprietary? What’s their plan for making sure the algorithm doesn’t start making mistakes over time (algorithmic drift)? Capital Efficiency: This assesses whether the business model is viable and can scale. Key questions include:
• Reimbursement Pathways: Is there a clear way for hospitals to get paid for using this? Established CPT codes (Category I or III) or a shot at NTAP are what you’re looking for. Without this, it’s just a cost center.
• Implementation Costs and Time to Value: How painful and expensive is it to get this thing installed and working with the hospital’s existing IT? And how fast does it start delivering a measurable return?
• Scalability and Market Adoption: Can this be sold to a wide range of hospitals, not just a few academic centers? Can they prove a positive ROI for different types of health systems?
• Unit Economics: On a per-patient or per-procedure basis, is the AI solution clearly cheaper or more effective than the old way of doing things? Using this rubric helps investors get past the flashy valuations and see which cardiovascular AI platforms are actually built to deliver a sustainable ROI. Knowing the difference between a true SaMD with clinical endpoints and an automation tool with unproven savings is what separates a good investment from a write-off. Framework for evaluating healthcare AI ROI